AU2004216360B2 - Pharmaceutical composition for treatment of drug dependence - Google Patents

Pharmaceutical composition for treatment of drug dependence Download PDF

Info

Publication number
AU2004216360B2
AU2004216360B2 AU2004216360A AU2004216360A AU2004216360B2 AU 2004216360 B2 AU2004216360 B2 AU 2004216360B2 AU 2004216360 A AU2004216360 A AU 2004216360A AU 2004216360 A AU2004216360 A AU 2004216360A AU 2004216360 B2 AU2004216360 B2 AU 2004216360B2
Authority
AU
Australia
Prior art keywords
mice
dependence
cocaine
morphine
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004216360A
Other languages
English (en)
Other versions
AU2004216360A1 (en
AU2004216360A2 (en
Inventor
Takatoshi Hikida
Shigetada Nakanishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of AU2004216360A1 publication Critical patent/AU2004216360A1/en
Publication of AU2004216360A2 publication Critical patent/AU2004216360A2/en
Assigned to EISAI R & D MANAGEMENT CO., LTD. reassignment EISAI R & D MANAGEMENT CO., LTD. Request for Assignment Assignors: SHIRANKAI KYOTO UNIVERSITY FACULTY OF MEDICINE ALUMNI ASSOCIATION INC.
Application granted granted Critical
Publication of AU2004216360B2 publication Critical patent/AU2004216360B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2004216360A 2003-02-27 2004-02-26 Pharmaceutical composition for treatment of drug dependence Ceased AU2004216360B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44986803P 2003-02-27 2003-02-27
US60/449,868 2003-02-27
PCT/JP2004/002301 WO2004075916A1 (en) 2003-02-27 2004-02-26 Pharmaceutical composition for treatment of drug dependence

Publications (3)

Publication Number Publication Date
AU2004216360A1 AU2004216360A1 (en) 2004-09-10
AU2004216360A2 AU2004216360A2 (en) 2004-09-10
AU2004216360B2 true AU2004216360B2 (en) 2009-09-17

Family

ID=32927586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004216360A Ceased AU2004216360B2 (en) 2003-02-27 2004-02-26 Pharmaceutical composition for treatment of drug dependence

Country Status (8)

Country Link
US (1) US20060058336A1 (cg-RX-API-DMAC7.html)
EP (1) EP1603595B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006519225A (cg-RX-API-DMAC7.html)
AT (1) ATE487492T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004216360B2 (cg-RX-API-DMAC7.html)
CA (1) CA2516618A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004029993D1 (cg-RX-API-DMAC7.html)
WO (1) WO2004075916A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
AU2002340232A1 (en) * 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
WO2006013546A2 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Process for the preparation of pure galantamine
RU2491067C2 (ru) * 2007-08-06 2013-08-27 Байотай Терапис, Инк Способы лечения зависимости
CN102573848A (zh) * 2009-04-24 2012-07-11 济州大学校产学协力团 含有去甲加兰他敏化合物作为活性成分的用于预防和治疗脱发症的组合物
KR101037235B1 (ko) 2009-04-24 2011-05-25 충남대학교산학협력단 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 방지 및 발모 개선용 조성물
KR101037237B1 (ko) 2009-04-24 2011-05-25 충남대학교산학협력단 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 질환의 예방 및 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643905A (en) * 1993-01-23 1997-07-01 Therapie-System Gmbh & Co., Kg Pharmaceutical formulation for the treatment of nicotine dependence
US5877172A (en) * 1995-03-17 1999-03-02 Lts Lohmann Therapie-Systeme Gmbh Process for isolating galanthamine
WO2003032914A2 (en) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
US20040116406A1 (en) * 2001-04-24 2004-06-17 Klaus Opitz Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5262165A (en) * 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DE69229781T2 (de) * 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
ES2223049T3 (es) * 1994-04-29 2005-02-16 Pfizer Inc. Amidas aciclicas y ciclicas novedosas como estimuladores de la liberacion de neurotransmisores.
PL181582B1 (pl) * 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
US5824684A (en) * 1997-02-21 1998-10-20 Synapse Pharmaceuticals International, Inc. Method for treating drug and alcohol addiction
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
DK1024807T3 (da) * 1997-08-08 2003-08-04 Medosan Ricerca Srl Anvendelse af forbindelsen 2-methoxyphenyl-1-methyl-5p-methylbenzoyl-pyrrol-2-acetamidoacetat for fremstilling af et anti-inflammatorisk medikament med forhindring af gastrisk hypersecernering og forstyrrelse af nyrefunktionen
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
JP3992806B2 (ja) * 1997-12-12 2007-10-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 ドネペジル中間体の製造法
IL125809A (en) * 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
DE60124730T2 (de) * 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
WO2002049459A1 (en) * 2000-12-20 2002-06-27 Michigan Biotechnology Institute Soy milk juice beverage
WO2003024450A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
JP2004189706A (ja) * 2002-12-13 2004-07-08 Eisai Co Ltd 高度アルツハイマー型痴呆治療剤
US20050018839A1 (en) * 2003-07-23 2005-01-27 Weiser William Bruce Electronic device cradle organizer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643905A (en) * 1993-01-23 1997-07-01 Therapie-System Gmbh & Co., Kg Pharmaceutical formulation for the treatment of nicotine dependence
US5877172A (en) * 1995-03-17 1999-03-02 Lts Lohmann Therapie-Systeme Gmbh Process for isolating galanthamine
US20040116406A1 (en) * 2001-04-24 2004-06-17 Klaus Opitz Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances
WO2003032914A2 (en) * 2001-10-17 2003-04-24 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOROWSKI, T. et al. Society for Neuroscience Abstracts. Vol. 26(1-2) Abstract No. 293.18 *
KRUSZEWSKA, A et al. Acta Poloniae Pharmaceutica. Vol.41(3): 381-384, 1985 *
MAJEWSKA, M. et al. Society for Neuroscience Abstracts. Vol.26(1-2) Abstract No. 681.3 *
WONG, C et al. European Journal of Pharmacology. Vol.56: 115-121, 1979 *

Also Published As

Publication number Publication date
US20060058336A1 (en) 2006-03-16
WO2004075916A1 (en) 2004-09-10
EP1603595A4 (en) 2008-04-16
EP1603595A1 (en) 2005-12-14
JP2006519225A (ja) 2006-08-24
DE602004029993D1 (de) 2010-12-23
AU2004216360A1 (en) 2004-09-10
CA2516618A1 (en) 2004-09-10
EP1603595B1 (en) 2010-11-10
AU2004216360A2 (en) 2004-09-10
ATE487492T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
JP3778923B2 (ja) ベンゾジアゼピンによる治療における改善
US5039680A (en) New use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5198459A (en) Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
JPH06507617A (ja) 疲労症候群の治療
Seidel et al. Alpha-2 adrenergic modulation of sleep: time-of-day-dependent pharmacodynamic profiles of dexmedetomidine and clonidine in the rat.
JP2011057700A (ja) 神経変性を処置するためのα2Bまたは2B/2Cアドレナリン受容体アゴニスト
EP1603595B1 (en) Pharmaceutical composition for treatment of drug dependence
JP2007502297A (ja) コリンエステラーゼ阻害剤を用いる睡眠障害の処置
US6670356B2 (en) Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
CA2262612A1 (en) Method for treating mental retardation
Bowersox et al. SNX-111
US6117890A (en) Method for treating bipolar disorder
EP0821955B1 (en) Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating bipolar disorder
US5519044A (en) Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
EP1559447A1 (en) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
Aceto The antinicotinic effects of drugs with clinically useful sedative-antianxiety properties
US20230201217A1 (en) 18-mc for treatment of substance use disorders
US20250367189A1 (en) 2-bromo-lysergic acid diethylamide for substance abuse
US6090829A (en) Method for treating excessive aggression
CA2261676A1 (en) Method for treating excessive aggression
Mason Jr Dynorphin A peptide involvement in the development of tolerance to Delta9-tetrahydrocannabinol-induced antinociception
HK1008932A (en) Use of 3-(4-hexyloxy-1,2,5-thiadiazol -3-yl)-1,2,5,6,-tetrahydro-1-methylpyridine (xanomeline) for treating bipolar disorder
MXPA99001029A (en) Method for treating bipolar disorder
HK1008931A (en) Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline ) for treating excessive aggression
HK1081880B (en) Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 26 AUG 2005

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: DELETE COINVENTOR PASTAN, IRA

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 02 MAR 2007

PC1 Assignment before grant (sect. 113)

Owner name: EISAI R & D MANAGEMENT CO., LTD.

Free format text: FORMER APPLICANT(S): SHIRANKAI KYOTO UNIVERSITY FACULTY OF MEDICINE ALUMNI ASSOCIATION INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired